SE0102858D0 - N-type calcium channel antagonists for the treatment of pain - Google Patents

N-type calcium channel antagonists for the treatment of pain

Info

Publication number
SE0102858D0
SE0102858D0 SE0102858A SE0102858A SE0102858D0 SE 0102858 D0 SE0102858 D0 SE 0102858D0 SE 0102858 A SE0102858 A SE 0102858A SE 0102858 A SE0102858 A SE 0102858A SE 0102858 D0 SE0102858 D0 SE 0102858D0
Authority
SE
Sweden
Prior art keywords
sup
treatment
pain
calcium channel
type calcium
Prior art date
Application number
SE0102858A
Other languages
English (en)
Swedish (sv)
Inventor
Amico Derin D
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0102858A priority Critical patent/SE0102858D0/xx
Publication of SE0102858D0 publication Critical patent/SE0102858D0/xx
Priority to JP2003523224A priority patent/JP2005508894A/ja
Priority to PCT/SE2002/001521 priority patent/WO2003018561A1/en
Priority to EP02760975A priority patent/EP1430030B1/en
Priority to US10/488,025 priority patent/US7153865B2/en
Priority to AT02760975T priority patent/ATE295837T1/de
Priority to DE60204232T priority patent/DE60204232T2/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
SE0102858A 2001-08-27 2001-08-27 N-type calcium channel antagonists for the treatment of pain SE0102858D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE0102858A SE0102858D0 (sv) 2001-08-27 2001-08-27 N-type calcium channel antagonists for the treatment of pain
JP2003523224A JP2005508894A (ja) 2001-08-27 2002-08-23 痛みの治療のためのｎ型カルシウムチャネルアンタゴニスト
PCT/SE2002/001521 WO2003018561A1 (en) 2001-08-27 2002-08-23 N-type calcium channel antagonists for the treatment of pain
EP02760975A EP1430030B1 (en) 2001-08-27 2002-08-23 N-type calcium channel antagonists for the treatment of pain
US10/488,025 US7153865B2 (en) 2001-08-27 2002-08-23 N-type calcium channel antagonists for the treatment of pain
AT02760975T ATE295837T1 (de) 2001-08-27 2002-08-23 Antagonisten für calciumkanäle vom n-typ zur behandlung von schmerzen
DE60204232T DE60204232T2 (de) 2001-08-27 2002-08-23 Antagonisten für calciumkanäle vom n-typ zur behandlung von schmerzen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102858A SE0102858D0 (sv) 2001-08-27 2001-08-27 N-type calcium channel antagonists for the treatment of pain

Publications (1)

Publication Number Publication Date
SE0102858D0 true SE0102858D0 (sv) 2001-08-27

Family

ID=20285150

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102858A SE0102858D0 (sv) 2001-08-27 2001-08-27 N-type calcium channel antagonists for the treatment of pain

Country Status (7)

Country Link
US (1) US7153865B2 (xx)
EP (1) EP1430030B1 (xx)
JP (1) JP2005508894A (xx)
AT (1) ATE295837T1 (xx)
DE (1) DE60204232T2 (xx)
SE (1) SE0102858D0 (xx)
WO (1) WO2003018561A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US7223754B2 (en) 2003-03-10 2007-05-29 Dynogen Pharmaceuticals, Inc. Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders
JP2006519846A (ja) * 2003-03-10 2006-08-31 シェーリング　コーポレイション 複素環式キナーゼインヒビター：使用および合成の方法
WO2004080444A2 (en) * 2003-03-10 2004-09-23 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using cav2.2 subunit calcium channel modulators
US7125848B2 (en) 2003-06-13 2006-10-24 Dynogen Pharmaceuticals, Inc. Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators
WO2006058201A2 (en) * 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
SI1963280T1 (sl) 2005-12-22 2016-02-29 Newron Pharmaceuticals S.P.A. 2-feniletilamino derivati kot modulatorji kalcijevih in/ali natrijevih kanalčkov
US8519000B2 (en) 2007-06-15 2013-08-27 Newron Pharmaceuticals S.P.A. Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
JP5827627B2 (ja) 2009-11-07 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ＴＧＦ−β受容体キナーゼ阻害剤としてのヘテロアリールアミノキノリン
PL2723710T3 (pl) 2011-06-27 2017-02-28 Newron Pharmaceuticals S.P.A. Fluorowane pochodne aryloalkiloaminokarboksyamidowe
EP3632426A1 (en) * 2013-02-01 2020-04-08 Wellstat Therapeutics Corporation Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
MX367420B (es) 2013-03-14 2019-08-21 Convergene Llc Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
AU2016361441B2 (en) * 2015-11-25 2021-08-12 Convergene Llc Bicyclic BET bromodomain inhibitors and uses thereof
CN111032629A (zh) * 2017-08-29 2020-04-17 朱拉蓬基金会 喹啉和萘啶的衍生物和组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1573186A (en) * 1977-09-14 1980-08-20 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
WO2000064877A1 (en) * 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands

Also Published As

Publication number Publication date
EP1430030A1 (en) 2004-06-23
EP1430030B1 (en) 2005-05-18
DE60204232T2 (de) 2006-01-26
ATE295837T1 (de) 2005-06-15
JP2005508894A (ja) 2005-04-07
US20050131020A1 (en) 2005-06-16
WO2003018561A1 (en) 2003-03-06
US7153865B2 (en) 2006-12-26
DE60204232D1 (de) 2005-06-23

Similar Documents

Publication Publication Date Title
SE0004053D0 (sv) N-type calcium channel antagonists for the treatment of pain
EA200401169A1 (ru) Аминометилзамещенные тетрациклиновые соединения
NO20026064D0 (no) Nye forbindelser
DE60334379D1 (de) Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung
ATE365703T1 (de) Substituierte 1,3-diphenylprop-2-en-1-on derivate,deren herstellung und anwendungen
PT1157037E (pt) Conjugados de gcsf
SE0102858D0 (sv) N-type calcium channel antagonists for the treatment of pain
NO20023934D0 (no) Nye forbindelser
SE9802729D0 (sv) Novel Compounds
SE0004054D0 (sv) N-type calcium channel antagonists for the treatment of pain
SE9802208D0 (sv) Novel compounds
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
AR021695A1 (es) 4,5-pirazinoxindoles, composicion farmaceutica y uso
SE0003476D0 (sv) Compounds
SE0101038D0 (sv) Novel compounds
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
SE0203070D0 (en) Novel compounds
SE0203303D0 (sv) Novel Compounds
SE9802937D0 (sv) Novel compounds
ATE417856T1 (de) Motilidverbindungen
SE0303280D0 (sv) Novel compounds
SE0203300D0 (sv) Novel Compounds
SE0302755D0 (sv) Novel compounds
SE9504662D0 (sv) New compounds
SE0004056D0 (sv) N-type calcium channel antagonists for the treatment of pain